Get the Stockscreener App
54.15
0.10%
-0.0638
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $54.15, with a volume of 1.73M.
It is down -0.10% in the last 24 hours and up +10.07% over the past month.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$54.21
Open:
$54.21
24h Volume:
1.73M
Relative Volume:
0.11
Market Cap:
$110.23B
Revenue:
$48.03B
Net Income/Loss:
$6.05B
P/E Ratio:
18.28
EPS:
2.9615
Net Cash Flow:
$15.30B
1W Performance:
-1.01%
1M Performance:
+10.07%
6M Performance:
+16.99%
1Y Performance:
-4.25%
1-Day Range:
$54.03
$54.28
1-Week Range:
$53.92
$55.04
52-Week Range:
$42.52
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
54.15 | 110.36B | 48.03B | 6.05B | 15.30B | 2.9615 |
|
LLY
Lilly Eli Co
|
1,077.99 | 966.40B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
207.07 | 498.51B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
229.64 | 406.04B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
138.31 | 266.17B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
105.50 | 263.24B | 63.90B | 19.05B | 13.05B | 7.5596 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
Bristol-Myers Squibb stock edges higher as Wall Street drifts into year-end — what’s next for BMY - ts2.tech
Goldman Sachs Raises Bristol-Myers (BMY) Target, Keeps Neutral Rating - Finviz
BMY vs AMGN: Which Biotech Stock Is More Resilient Now? - Finviz
Is Bristol Myers Squibb a buy, sell, or hold in 2026? - MSN
Is Bristol Myers Squibb a Buy, Sell, or Hold in 2026? - The Motley Fool
Got $500? 3 Dividend-Paying Healthcare Stocks to Buy and Hold Forever - Finviz
Got $500? 3 Dividend-Paying Healthcare Stocks to Buy and Hold Forever - The Motley Fool
Bristol-Myers Squibb Stock Finds a Floor as Wall Street Bets on a Late-Cycle Rebound - AD HOC NEWS
Diversified Trust Co Has $4.56 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Inside Bristol-Myers Squibb: How a Quiet Pharma Giant Is Re?Architecting the Future of Cancer and Im - AD HOC NEWS
What does Wall Street think about Bristol-Myers Squibb Company (BMY)? - MSN
What Does Wall Street Think About Bristol-Myers Squibb Company (BMY)? - Finviz
10 Best Affordable Healthcare Stocks to Buy Now - Insider Monkey
Bristol-Myers Squibb Stock: Defensive Pharma Giant Tests Investor Patience As Wall Street Turns Sele - AD HOC NEWS
Bristol Myers Squibb stock slips today as year-end trading thins and dividend date nears - ts2.tech
Bristol Myers Squibb (BMY) Stock: Weekend News, Analyst Targets, Dividend Update, and What to Watch Before Monday’s Open - ts2.tech
Bristol-Myers Squibb Charts a New Strategic Course with U.S. Government Pact - AD HOC NEWS
Bristol-Myers Squibb (BMY) Stock: Weekend Market Close, Fresh Institutional Filings, and What to Watch Before Monday’s Open - ts2.tech
Meyer Handelman Co. Sells 52,438 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Trust Co. of Toledo NA OH Increases Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb (BMY) Stock News, Forecasts and Outlook as of Dec. 25, 2025: Breyanzi FDA Win, Eliquis Medicaid Deal, and 2026 Catalysts - ts2.tech
Got $1,000? 2 High-Yield Healthcare Stocks to Buy and Hold Forever - Finviz
Bristol-Myers Squibb: Contrarian Buy For Dividend Hunters, Despite Mounting Growth Headwinds - Seeking Alpha
Bristol Myers Squibb: A Pharma Giant Trading Like Growth Is OverIt's Not - Seeking Alpha
Bristol Myers lines up many launches for India with 'AI' speed - The Economic Times
Bristol-Myers (BMY) Offers Eliquis Free to Medicaid Patients Under New Pricing Pact - Finviz
Is Bristol Myers Squibb (BMY) Still Undervalued After Its Recent Share Price Rebound? - Yahoo Finance UK
Bristol-Myers Squibb (BMY) Stock News Today: Supreme Court Bid, Drug-Pricing Deals, Dividend Boost, and 2026 Forecasts (Dec. 23, 2025) - ts2.tech
J&J, Bristol Myers Ask High Court to Review US Drug Price Cuts - Bloomberg Law News
Bristol-Myers Squibb Surges Into Year-End: Why BMY Still Looks Undervalued (NYSE:BMY) - Seeking Alpha
Bristol-Myers Squibb: Still Undervalued And Generating 4.65% Dividend Yield - Seeking Alpha
Bristol-Myers Squibb stock holds Buy rating at Guggenheim amid oHCM competition - Investing.com India
3 Top Value Stocks to Buy and Hold for 2026 - Morningstar
Harbour Biomed closes busy year with $1B+ BMS deal - BioWorld MedTech
Bristol-Myers Squibb (BMY) Stock After Hours Today, Dec. 22, 2025: What to Know Before the Market Opens Tuesday - ts2.tech
Exchange Traded Concepts LLC Purchases 83,214 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by First Bank & Trust - MarketBeat
Bristol-Myers Squibb Secures Regulatory Truce with Landmark U.S. Pricing Deal - AD HOC NEWS
Cytokinetics set to battle Bristol Myers as FDA approves heart drug - BioPharma Dive
BofA Upgrades Bristol-Myers Squibb (BMY) Stock to Buy from Neutral - Finviz
FDA Approves Bristol-Myers Squibb's Breyanzi as First-Ever CAR T Therapy for Rare Marginal Zone Lymphoma - Finviz
FDA Approves Bristol-Myers Squibb’s Breyanzi as First-Ever CAR T Therapy for Rare Marginal Zone Lymphoma - Insider Monkey
Flputnam Investment Management Co. Purchases 64,133 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
How Bristol Myers Squibb Company Equity Right stock compares to industry benchmarksEarnings Performance Report & Verified Swing Trading Watchlist - Улправда
Leerink Partners Sticks to Its Buy Rating for Bristol-Myers Squibb (BMY) - The Globe and Mail
Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal - Benzinga
US FDA approves Cytokinetics' heart disease drug - Reuters
Nine biopharmas agree to most-favoured nation drug pricing in the US - FirstWord Pharma
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance
Cytokinetics Takes On Bristol With Newly Approved Heart Drug - Bloomberg.com
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):